Editorial
|
|
|
|
|
Testosterone mongering
|
|
|
|
Marketing Authorisations
|
|
|
|
|
Too many unknowns for an anti-IgE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For a few patients with close monitoring
|
|
|
|
|
|
|
|
|
|
Just another intravenous me-too drug
|
|
|
|
|
|
|
|
|
|
|
|
Don't use to stimulate women’s sexual desire
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Just another TNF alpha antagonist
|
|
|
|
|
|
|
|
|
|
Confirmed risks not emphasised in the SPC
|
|
|
|
|
|
|
|
|
|
Caution is needed due to long-term risks
|
|
|
|
|
|
|
|
|
|
Deliberate lack of precision
|
|
|
|
|
|
|
|
|
|
Second-line treatment of iron overload in the absence of a better alternative
|
|
|
|
|
|
|
|
|
|
For iron overload : only a third-line option
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
Hormone therapy inappropriate
|
|
|
|
|
|
|
|
|
|
Little or no different from placebo
|
|
|
|
|
|
|
|
|
|
Adapt steroid therapy to severity
|
|
|
|
|
|
|
|
|
|
|
|
|
|